^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    DK210 (EGFR)

    i
    Other names: DK210 (EGFR), DK210, DK2-10
    Associations

    News

    Trials
    Company:
    Deka BioSci
    Drug class:
    EGFR inhibitor, IL-2 modulator, IL-10 modulator
    Related drugs:
    Associations

    News

    Trials
    6ms
    DEKA-1: Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors (clinicaltrials.gov)
    P1, N=39, Active, not recruiting, DEKA Biosciences | Recruiting --> Active, not recruiting | N=60 --> 39 | Trial primary completion date: Mar 2025 --> Jul 2025
    Enrollment closed • Enrollment change • Trial primary completion date • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
    |
    EGFR expression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • carboplatin • paclitaxel • 5-fluorouracil • capecitabine • oxaliplatin • DK210 (EGFR)
    11ms
    DEKA-1: Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors (clinicaltrials.gov)
    P1, N=60, Recruiting, DEKA Biosciences | Trial completion date: Feb 2025 --> Oct 2025 | Trial primary completion date: Sep 2024 --> Mar 2025
    Trial completion date • Trial primary completion date • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
    |
    EGFR expression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • carboplatin • paclitaxel • 5-fluorouracil • capecitabine • oxaliplatin • DK210 (EGFR)
    almost2years
    Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors (clinicaltrials.gov)
    P1, N=60, Recruiting, DEKA Biosciences
    Trial completion date • Trial primary completion date • IO biomarker • Metastases
    |
    EGFR (Epidermal growth factor receptor) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
    |
    EGFR expression • EGFR overexpression • IL10 elevation • IL2 expression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • carboplatin • paclitaxel • 5-fluorouracil • capecitabine • oxaliplatin • DK210 (EGFR)
    over2years
    DEKA-1 a dose-finding phase I trial: Observing safety and biomarkers using DK210 (EGFR) for inoperable locally advanced and/or metastatic EGFR+ tumors with progressive disease failing systemic therapy (ESMO 2023)
    Key eligibility criteria include: 1) confirmed progressive disease on at least one line of systemic treatment, 2) EGFR overexpression or amplification documented in histology reports, 3) at least a 4 week or 5 half-lives window since last treatment, and 4) excluding subjects with long QT syndrome, multiple myeloma, multiple sclerosis, myasthenia gravis or uncontrolled infectious, psychiatric, neurologic, or cancer disease. Plasma and tissue samples will be investigated for pharmacodynamic and predictive biomarkers and genetic signatures associated with IFN-gamma secretion, aiming to select subjects for treatment in phase 2.
    Clinical • P1 data • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    EGFR (Epidermal growth factor receptor) • IFNG (Interferon, gamma) • IL10 (Interleukin 10)
    |
    EGFR overexpression
    |
    DK210 (EGFR)
    almost3years
    Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors (clinicaltrials.gov)
    P1, N=60, Recruiting, DEKA Biosciences | Not yet recruiting --> Recruiting
    Enrollment open • IO biomarker • Metastases
    |
    EGFR (Epidermal growth factor receptor) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • IL1B (Interleukin 1, beta)
    |
    EGFR expression • EGFR overexpression • IL10 elevation • IL2 expression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • carboplatin • paclitaxel • 5-fluorouracil • capecitabine • oxaliplatin • DK210 (EGFR)
    almost3years
    Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors (clinicaltrials.gov)
    P1, N=60, Not yet recruiting, DEKA Biosciences
    New P1 trial • IO biomarker • Metastases
    |
    EGFR (Epidermal growth factor receptor) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • IL1B (Interleukin 1, beta)
    |
    EGFR overexpression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • carboplatin • paclitaxel • 5-fluorouracil • capecitabine • oxaliplatin • DK210 (EGFR)